Time Restricted Eating As Treatment (TREAT) for Diabetes Mellitus: A Pre-Post 12 Week Study on the Effectiveness of Intermittent Fasting in Asians With Type 2 Diabetes Mellitus
NCT ID: NCT03940482
Last Updated: 2023-09-07
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Clinical Phase
NA
Total Enrollment
50 participants
Study Classification
INTERVENTIONAL
Study Start Date
2019-01-14
Study Completion Date
2023-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Type 2 Diabetes Mellitus (DM) is a silent epidemic that affects 11.3% of Singaporeans. It has numerous clinical sequelae including macrovascular and microvascular disease. Nutritional therapy has been widely accepted as being safe and affordable as compared to pharmacotherapy. It is estimated that current nutritional therapy is able to reduce HbA1c levels by 1 to 2 percent under ideal circumstances. A weight loss of \>5% is needed to have any significant beneficial effects on the levels of HbA1c, lipids, and blood pressure. This requires extensive modification of lifestyle, calorie restriction, regular exercise, and close supervision by health care professionals; impracticable for most patients. Intermittent Fasting that has been shown to be effective in improving the metabolic state of human subjects. The investigators ask if a simpler dietary regime based on time restricted eating would produce the necessary weight loss and good metabolic outcome.
In this pilot single arm pre-post study, 50 adult diabetic patients will be educated on Time Restricted Eating As Treatment (TREAT). Under this intervention, subjects will skip one meal a day and aim for a fasting period 16 hours a day. In the 8 hours where eating is permitted, subjects are encouraged to eat normally based on what is recommended for diabetic patients in usual care. Relevant clinical parameters, such as blood glucose control, lipid and triglyceride levels and anthropometry will be monitored over a 12-week period.
This study would have major clinical impact if it is found that TREAT can result in the improvement of cardiometabolic parameters and is practicable and sustainable in a real world setting.
In this pilot single arm pre-post study, 50 adult diabetic patients will be educated on Time Restricted Eating As Treatment (TREAT). Under this intervention, subjects will skip one meal a day and aim for a fasting period 16 hours a day. In the 8 hours where eating is permitted, subjects are encouraged to eat normally based on what is recommended for diabetic patients in usual care. Relevant clinical parameters, such as blood glucose control, lipid and triglyceride levels and anthropometry will be monitored over a 12-week period.
This study would have major clinical impact if it is found that TREAT can result in the improvement of cardiometabolic parameters and is practicable and sustainable in a real world setting.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effect of Late Night Meals on Fasting Glucose in Type 2 Diabetes Patients
NCT00986700
Fasting Hyperglycemia
COMPLETED
NA
Effects of Fixed Meals With Special Formulated Rice on Blood Glucose Levels of Healthy Volunteers.
NCT03985566
Diabetes Mellitus, Type 2
COMPLETED
NA
The Effect of Meal Replacement on the Time to Reach the Blood Glucose Target in Patients With Type 2 Diabetes Mellitus
NCT05365152
Diabetes
Blood Sugar; High
UNKNOWN
NA
The Effects of a Novel Lifestyle Intervention Program on Insulin Sensitivity in Type 2 Diabetes
NCT04509245
Type 2 Diabetes
Fatty Liver, Nonalcoholic
COMPLETED
NA
Diabetes-Specific Formula in Individuals With Type 2 Diabetes
NCT04303754
Diabetes Mellitus, Type 2
COMPLETED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Nutritional therapy for diabetes mellitus is widely accepted as safe and affordable when compared to pharmacotherapy. However, the efficacy of the present state of nutritional therapy based on current recommendations is poor. It is estimated that nutritional therapy is able to reduce HbA1c levels by 1 to 2 percent under ideal circumstances. A weight loss of \>5% is needed to have any significant beneficial effects on the levels of HbA1c, lipids, and blood pressure. This would require extensive modification of lifestyle, including calorie restriction, regular exercise, and close supervision by health care professionals. For the majority of patients, adherence to such a regime on a long-term basis is not achievable or practical.Considerable effort is required to educate and reinforce the complex behavioural changes needed. A simpler dietary regime that would produce the necessary weight loss and good metabolic outcome is needed.
Rationale for use of Intermittent Fasting as Nutritional Therapy: Practicability, Efficacy and Safety.
Intermittent fasting (IF) has been practiced by humans since ancient times, out of necessity and for religious purposes. Numerous regimens of intermittent fasting exist:
1. Alternate-day fasting, with either a total fast or restriction of energy 60-70% below estimated requirements on alternate days.
2. Modified Fasting Regimens (such as the 5:2 diet which involves severe energy restriction for 2 non-consecutive days in a week and ad libitum eating for the other 5 days), a variant of alternate-day fasting.
3. Time-restricted Feeding where intake is restricted to a pre-defined time window daily, and fasting occurs for 12-21 hours of the day.
There is experimental and evolutionary evidence across microbes and animals that such fasting improves cardiometabolic health and survival. In mice, the preservation of beta cell function occurs through the mechanism of autophagy during fasting, and survival is prolonged in bacteria, yeasts, worms and mice when fasting that has been attributed to an alternative ketone-body like energy source during periods of caloric deprivation. The mechanisms of action proposed are that fasting triggers adaptive cellular stress responses, resulting in an enhanced ability to cope with more severe stress and counteract disease processes. In addition, by protecting cells from DNA damage, suppressing cell growth and enhancing apoptosis of damaged cells, fasting could retard and/or prevent the formation and growth of cancers.
In humans, there is increasing evidence that intermittent fasting produces improvements in various metabolic parameters that are potentially beneficial to Type 2 Diabetics, such as improvements in glycaemic control, lipid profiles and weight loss. For example, Carter reported equivalent reductions in HbA1c in individuals with Type 2 diabetes with 12 weeks of Intermittent Energy Restriction (IER) or Continuous Energy Restriction (CER) which had been achieved with greater reductions in insulin medications within the IER group. Arnason demonstrated improved glycaemic control and weight in 10 community-dwelling middle-aged Type 2 Diabetic adults over a six week period in which subjects underwent Time-restricted feeding intervention for 2 weeks.
Other than glycaemic control, intermittent fasting also benefits other cardiometabolic parameters. Body fat, LDL-Cholesterol, Triglycerides and weight circumference were reduced with improvements in glucose metabolism in obese subjects in response to an alternate day modified fast. Glucose metabolism, reflected by decrease in fasting insulin, improved in non-obese subjects when subjected to 3 weeks of alternate day fasting.
Alternate day fasting has been associated with hunger, distraction with lower perceived work performance and lower mood reported across some of its' human studies.Modified Fasting Regimens, though they largely result in clinically and statistically significant weight loss of between 3.2-8.0% have up to 15% of participants reporting negative side effects, such as feeling cold, irritable, low energy levels or hunger.
Time-restricted Feeding (TRF), typically have daily fasting intervals of 12-21 hours per day. There were no mean changes in tension, depression, anger, vigor, fatigue or confusion when subjects of a crossover trial were consuming one meal a day as opposed to an isocaloric diet consumed as three meals a day. There is observational evidence from Ramadan studies of Diabetic patients that glycaemic control and lipid parameters improve over a 4-week fasting period. Only one cross-over controlled study in healthy middle-aged adults has reported on metabolic outcomes with Time-restricted Feeding. Stote et al. found both pro-atherogenic changes (increased LDL cholesterol) and anti- atherogenic changes (increased HDL cholesterol and decreased TG) following 8 weeks of limiting food intake to one evening meal. This might have been confounded by circadian variations of baseline and post-intervention blood measurements, that were taken in the morning and evening respectively. Thus far, there are no publications on interventional studies on Time-restricted Feeding in diabetics to the investigators' knowledge. Time-restricted Feeding appears to be the most practical and easy to learn regime among all the intermittent fasting variations.
The investigators decided to adopt TRF and make it into a standardized regime that requires the subject to aim for a continuous fasting duration of 16 hours per day. The instruction can be taught to patients in a 30 minute session and opportunistic reinforcements. This mimics a real world counselling encounter between a primary care physician and patient with diabetes mellitus. The investigators call this regime Time Restricted Eating As Treatment (TREAT). This 12-week study of TREAT in adult patients with Type 2 Diabetes Mellitus aims to explore if this simplified form of intermittent fasting can result in clinically and statistically significant reductions in weight, improved glycaemic control and metabolic parameters including hyperinsulinemia, with particular emphasis on an Asian population. Accordingly, the investigators plan to recruit 50 community dwelling type 2 diabetic patients and instruct them on TREAT in a clinic setting. Patients will then be followed up with anthropometry and biochemical markers pertaining to diabetes during the study visits.
Rationale for use of Intermittent Fasting as Nutritional Therapy: Practicability, Efficacy and Safety.
Intermittent fasting (IF) has been practiced by humans since ancient times, out of necessity and for religious purposes. Numerous regimens of intermittent fasting exist:
1. Alternate-day fasting, with either a total fast or restriction of energy 60-70% below estimated requirements on alternate days.
2. Modified Fasting Regimens (such as the 5:2 diet which involves severe energy restriction for 2 non-consecutive days in a week and ad libitum eating for the other 5 days), a variant of alternate-day fasting.
3. Time-restricted Feeding where intake is restricted to a pre-defined time window daily, and fasting occurs for 12-21 hours of the day.
There is experimental and evolutionary evidence across microbes and animals that such fasting improves cardiometabolic health and survival. In mice, the preservation of beta cell function occurs through the mechanism of autophagy during fasting, and survival is prolonged in bacteria, yeasts, worms and mice when fasting that has been attributed to an alternative ketone-body like energy source during periods of caloric deprivation. The mechanisms of action proposed are that fasting triggers adaptive cellular stress responses, resulting in an enhanced ability to cope with more severe stress and counteract disease processes. In addition, by protecting cells from DNA damage, suppressing cell growth and enhancing apoptosis of damaged cells, fasting could retard and/or prevent the formation and growth of cancers.
In humans, there is increasing evidence that intermittent fasting produces improvements in various metabolic parameters that are potentially beneficial to Type 2 Diabetics, such as improvements in glycaemic control, lipid profiles and weight loss. For example, Carter reported equivalent reductions in HbA1c in individuals with Type 2 diabetes with 12 weeks of Intermittent Energy Restriction (IER) or Continuous Energy Restriction (CER) which had been achieved with greater reductions in insulin medications within the IER group. Arnason demonstrated improved glycaemic control and weight in 10 community-dwelling middle-aged Type 2 Diabetic adults over a six week period in which subjects underwent Time-restricted feeding intervention for 2 weeks.
Other than glycaemic control, intermittent fasting also benefits other cardiometabolic parameters. Body fat, LDL-Cholesterol, Triglycerides and weight circumference were reduced with improvements in glucose metabolism in obese subjects in response to an alternate day modified fast. Glucose metabolism, reflected by decrease in fasting insulin, improved in non-obese subjects when subjected to 3 weeks of alternate day fasting.
Alternate day fasting has been associated with hunger, distraction with lower perceived work performance and lower mood reported across some of its' human studies.Modified Fasting Regimens, though they largely result in clinically and statistically significant weight loss of between 3.2-8.0% have up to 15% of participants reporting negative side effects, such as feeling cold, irritable, low energy levels or hunger.
Time-restricted Feeding (TRF), typically have daily fasting intervals of 12-21 hours per day. There were no mean changes in tension, depression, anger, vigor, fatigue or confusion when subjects of a crossover trial were consuming one meal a day as opposed to an isocaloric diet consumed as three meals a day. There is observational evidence from Ramadan studies of Diabetic patients that glycaemic control and lipid parameters improve over a 4-week fasting period. Only one cross-over controlled study in healthy middle-aged adults has reported on metabolic outcomes with Time-restricted Feeding. Stote et al. found both pro-atherogenic changes (increased LDL cholesterol) and anti- atherogenic changes (increased HDL cholesterol and decreased TG) following 8 weeks of limiting food intake to one evening meal. This might have been confounded by circadian variations of baseline and post-intervention blood measurements, that were taken in the morning and evening respectively. Thus far, there are no publications on interventional studies on Time-restricted Feeding in diabetics to the investigators' knowledge. Time-restricted Feeding appears to be the most practical and easy to learn regime among all the intermittent fasting variations.
The investigators decided to adopt TRF and make it into a standardized regime that requires the subject to aim for a continuous fasting duration of 16 hours per day. The instruction can be taught to patients in a 30 minute session and opportunistic reinforcements. This mimics a real world counselling encounter between a primary care physician and patient with diabetes mellitus. The investigators call this regime Time Restricted Eating As Treatment (TREAT). This 12-week study of TREAT in adult patients with Type 2 Diabetes Mellitus aims to explore if this simplified form of intermittent fasting can result in clinically and statistically significant reductions in weight, improved glycaemic control and metabolic parameters including hyperinsulinemia, with particular emphasis on an Asian population. Accordingly, the investigators plan to recruit 50 community dwelling type 2 diabetic patients and instruct them on TREAT in a clinic setting. Patients will then be followed up with anthropometry and biochemical markers pertaining to diabetes during the study visits.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Type 2 Diabetes Mellitus
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Single Arm
Subjects will act as their own controls
Group Type
EXPERIMENTAL
Time Restricted Eating As Treatment (TREAT) for Diabetes.
Intervention Type
BEHAVIORAL
Participants will skip a meal every day and maintain a water only fast for 16 hours. A fasting diary is kept to track hours of fasting. Participants will follow this new pattern of eating for 12 weeks. They will visit the doctor's office at least 3 times in the course of the study and will be followed up with anthropometry (weight, BMI and waist circumference) and biochemical markers pertaining to Diabetes during the study visits. At 24 weeks, a follow up phone call will be made to check self-reported compliance to intermittent fasting.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Time Restricted Eating As Treatment (TREAT) for Diabetes.
Participants will skip a meal every day and maintain a water only fast for 16 hours. A fasting diary is kept to track hours of fasting. Participants will follow this new pattern of eating for 12 weeks. They will visit the doctor's office at least 3 times in the course of the study and will be followed up with anthropometry (weight, BMI and waist circumference) and biochemical markers pertaining to Diabetes during the study visits. At 24 weeks, a follow up phone call will be made to check self-reported compliance to intermittent fasting.
Intervention Type
BEHAVIORAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Subjects (male or female) ≥ 21 to 80 years of age at Visit 1.
2. Subjects newly diagnosed with Type II diabetes mellitus (DM) who are solely on dietary control.
3. Ability to sign written informed consent before any study-specific procedure.
4. Subject is considered reliable and capable of adhering to protocol.
5. Subjects with Body Mass Index (BMI)≥ 23.5kg/m2.
2. Subjects newly diagnosed with Type II diabetes mellitus (DM) who are solely on dietary control.
3. Ability to sign written informed consent before any study-specific procedure.
4. Subject is considered reliable and capable of adhering to protocol.
5. Subjects with Body Mass Index (BMI)≥ 23.5kg/m2.
Exclusion Criteria
1. Subjects on Type II diabetes medication.
2. Subjects with any of the following medical conditions:
* Congestive cardiac failure.
* Stage 4 or worse chronic kidney disease (i.e. eGFR \< 30 ml/min/1.73 m2)
* Child's B or worse liver cirrhosis.
* Any medical condition that in the opinion of the investigator could jeopardize or compromise the subject's ability to participate in the study.
3. Subject with previous or present history of eating disorder.
4. Subject not able to understand the informed consent form or fasting diary instructions.
5. Subject has participated in another study of an investigational medication or an investigational medical device within the last 30 days or is currently participating in these studies.
6. Subject is pregnant or lactating.
2. Subjects with any of the following medical conditions:
* Congestive cardiac failure.
* Stage 4 or worse chronic kidney disease (i.e. eGFR \< 30 ml/min/1.73 m2)
* Child's B or worse liver cirrhosis.
* Any medical condition that in the opinion of the investigator could jeopardize or compromise the subject's ability to participate in the study.
3. Subject with previous or present history of eating disorder.
4. Subject not able to understand the informed consent form or fasting diary instructions.
5. Subject has participated in another study of an investigational medication or an investigational medical device within the last 30 days or is currently participating in these studies.
6. Subject is pregnant or lactating.
Minimum Eligible Age
21 Years
Maximum Eligible Age
80 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Duke-NUS Graduate Medical School
OTHER
Sponsor Role
collaborator
Singapore General Hospital
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lee Kheng Hock
Role: PRINCIPAL_INVESTIGATOR
Singapore General Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Singapore General Hospital (Clinical Trials and Research Centre)
Singapore, , Singapore
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Singapore
References
Explore related publications, articles, or registry entries linked to this study.
Franz MJ, Boucher JL, Evert AB. Evidence-based diabetes nutrition therapy recommendations are effective: the key is individualization. Diabetes Metab Syndr Obes. 2014 Feb 24;7:65-72. doi: 10.2147/DMSO.S45140. eCollection 2014.
Reference Type
BACKGROUND
Franz MJ, Boucher JL, Rutten-Ramos S, VanWormer JJ. Lifestyle weight-loss intervention outcomes in overweight and obese adults with type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials. J Acad Nutr Diet. 2015 Sep;115(9):1447-63. doi: 10.1016/j.jand.2015.02.031. Epub 2015 Apr 29.
Reference Type
BACKGROUND
Patterson RE, Laughlin GA, LaCroix AZ, Hartman SJ, Natarajan L, Senger CM, Martinez ME, Villasenor A, Sears DD, Marinac CR, Gallo LC. Intermittent Fasting and Human Metabolic Health. J Acad Nutr Diet. 2015 Aug;115(8):1203-12. doi: 10.1016/j.jand.2015.02.018. Epub 2015 Apr 6. No abstract available.
Reference Type
BACKGROUND
Heilbronn LK, Smith SR, Martin CK, Anton SD, Ravussin E. Alternate-day fasting in nonobese subjects: effects on body weight, body composition, and energy metabolism. Am J Clin Nutr. 2005 Jan;81(1):69-73. doi: 10.1093/ajcn/81.1.69.
Reference Type
BACKGROUND
Halberg N, Henriksen M, Soderhamn N, Stallknecht B, Ploug T, Schjerling P, Dela F. Effect of intermittent fasting and refeeding on insulin action in healthy men. J Appl Physiol (1985). 2005 Dec;99(6):2128-36. doi: 10.1152/japplphysiol.00683.2005. Epub 2005 Jul 28.
Reference Type
BACKGROUND
Catenacci VA, Pan Z, Ostendorf D, Brannon S, Gozansky WS, Mattson MP, Martin B, MacLean PS, Melanson EL, Troy Donahoo W. A randomized pilot study comparing zero-calorie alternate-day fasting to daily caloric restriction in adults with obesity. Obesity (Silver Spring). 2016 Sep;24(9):1874-83. doi: 10.1002/oby.21581.
Reference Type
BACKGROUND
Williams KV, Mullen ML, Kelley DE, Wing RR. The effect of short periods of caloric restriction on weight loss and glycemic control in type 2 diabetes. Diabetes Care. 1998 Jan;21(1):2-8. doi: 10.2337/diacare.21.1.2.
Reference Type
BACKGROUND
Liu H, Javaheri A, Godar RJ, Murphy J, Ma X, Rohatgi N, Mahadevan J, Hyrc K, Saftig P, Marshall C, McDaniel ML, Remedi MS, Razani B, Urano F, Diwan A. Intermittent fasting preserves beta-cell mass in obesity-induced diabetes via the autophagy-lysosome pathway. Autophagy. 2017;13(11):1952-1968. doi: 10.1080/15548627.2017.1368596. Epub 2017 Nov 25.
Reference Type
BACKGROUND
Longo VD, Mattson MP. Fasting: molecular mechanisms and clinical applications. Cell Metab. 2014 Feb 4;19(2):181-92. doi: 10.1016/j.cmet.2013.12.008. Epub 2014 Jan 16.
Reference Type
BACKGROUND
Harvie M, Howell A. Potential Benefits and Harms of Intermittent Energy Restriction and Intermittent Fasting Amongst Obese, Overweight and Normal Weight Subjects-A Narrative Review of Human and Animal Evidence. Behav Sci (Basel). 2017 Jan 19;7(1):4. doi: 10.3390/bs7010004.
Reference Type
BACKGROUND
Carter S, Clifton PM, Keogh JB. The effects of intermittent compared to continuous energy restriction on glycaemic control in type 2 diabetes; a pragmatic pilot trial. Diabetes Res Clin Pract. 2016 Dec;122:106-112. doi: 10.1016/j.diabres.2016.10.010. Epub 2016 Oct 19.
Reference Type
BACKGROUND
Arnason TG, Bowen MW, Mansell KD. Effects of intermittent fasting on health markers in those with type 2 diabetes: A pilot study. World J Diabetes. 2017 Apr 15;8(4):154-164. doi: 10.4239/wjd.v8.i4.154.
Reference Type
BACKGROUND
Klempel MC, Kroeger CM, Varady KA. Alternate day fasting (ADF) with a high-fat diet produces similar weight loss and cardio-protection as ADF with a low-fat diet. Metabolism. 2013 Jan;62(1):137-43. doi: 10.1016/j.metabol.2012.07.002. Epub 2012 Aug 11.
Reference Type
BACKGROUND
Patterson RE, Sears DD. Metabolic Effects of Intermittent Fasting. Annu Rev Nutr. 2017 Aug 21;37:371-393. doi: 10.1146/annurev-nutr-071816-064634. Epub 2017 Jul 17.
Reference Type
BACKGROUND
Harvie M, Wright C, Pegington M, McMullan D, Mitchell E, Martin B, Cutler RG, Evans G, Whiteside S, Maudsley S, Camandola S, Wang R, Carlson OD, Egan JM, Mattson MP, Howell A. The effect of intermittent energy and carbohydrate restriction v. daily energy restriction on weight loss and metabolic disease risk markers in overweight women. Br J Nutr. 2013 Oct;110(8):1534-47. doi: 10.1017/S0007114513000792. Epub 2013 Apr 16.
Reference Type
BACKGROUND
Harvie MN, Pegington M, Mattson MP, Frystyk J, Dillon B, Evans G, Cuzick J, Jebb SA, Martin B, Cutler RG, Son TG, Maudsley S, Carlson OD, Egan JM, Flyvbjerg A, Howell A. The effects of intermittent or continuous energy restriction on weight loss and metabolic disease risk markers: a randomized trial in young overweight women. Int J Obes (Lond). 2011 May;35(5):714-27. doi: 10.1038/ijo.2010.171. Epub 2010 Oct 5.
Reference Type
BACKGROUND
Carlson O, Martin B, Stote KS, Golden E, Maudsley S, Najjar SS, Ferrucci L, Ingram DK, Longo DL, Rumpler WV, Baer DJ, Egan J, Mattson MP. Impact of reduced meal frequency without caloric restriction on glucose regulation in healthy, normal-weight middle-aged men and women. Metabolism. 2007 Dec;56(12):1729-34. doi: 10.1016/j.metabol.2007.07.018.
Reference Type
BACKGROUND
Al-Shafei AI. Ramadan fasting ameliorates oxidative stress and improves glycemic control and lipid profile in diabetic patients. Eur J Nutr. 2014 Oct;53(7):1475-81. doi: 10.1007/s00394-014-0650-y. Epub 2014 Jan 19.
Reference Type
BACKGROUND
Stote KS, Baer DJ, Spears K, Paul DR, Harris GK, Rumpler WV, Strycula P, Najjar SS, Ferrucci L, Ingram DK, Longo DL, Mattson MP. A controlled trial of reduced meal frequency without caloric restriction in healthy, normal-weight, middle-aged adults. Am J Clin Nutr. 2007 Apr;85(4):981-8. doi: 10.1093/ajcn/85.4.981.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TREAT-DM-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
The Effects of Mixed Grain on Blood Glucose and Insulin in Healthy Male
NCT01840982
COMPLETED
NA
To Evaluate the Impact of Consumption of a Bioactive Compound on Fasting Blood Glucose Levels in Asian Indians With Pre-diabetes
NCT06417840
RECRUITING
NA
The Impact of the Glycaemic Index (GI) on Daily Blood Glucose Profiles and Food Intake in Young Chinese Adult Males
NCT02340507
COMPLETED
NA
Postprandial Glycemic Response in Adults With Type 2 Diabetes
NCT05154045
COMPLETED
NA
Glycemic Evaluation of Okra Seed Noodles
NCT03990844
COMPLETED
NA
Acute and Long-term Health Effects of Various Carbohydrates on Blood Glucose Management in Humans
NCT06554002
COMPLETED
NA
Efficacy and Safety of Diabetes-specific Formula in Patients With Type 2 Diabetes Mellitus
NCT04622722
COMPLETED
NA
Diabetes Dietary Study- Low Carbohydrate and Low-Fat Diets in Type 2 Diabetes
NCT00795691
COMPLETED
NA
Assessing the Effects of a Buckwheat Beverage on Postprandial Glucose Metabolism on Healthy and T2D Individuals
NCT03923205
UNKNOWN
NA
Diabetes-Specific Formula on Long Term Glycemic Control
NCT04345497
COMPLETED
NA
Efficacy of Multigrain Supplementation in Type II Diabetes Mellitus
NCT04597229
COMPLETED
NA
Effect of Lycopene and Isoflavones on Glucose Metabolism
NCT01377961
WITHDRAWN
NA
Glycemic Index in Subjects With Diabetes Mellitus Insulin Requesting
NCT02881164
COMPLETED
NA
Short-term Effects of Carbohydrate-restricted Diet on Glycemic and Metabolic Control Among Children and Adolescent With Type 1 Diabetes Mellitus
NCT06699485
NOT_YET_RECRUITING
NA
The Effects of Soy Isoflavones to Improve the Metabolism of Glucose and Lipids
NCT00951912
COMPLETED
NA
Nutritional Prevention of Diabetes Mellitus Type 2
NCT03231839
COMPLETED
NA
Nut Intake At Night: Effect on Postprandial Glycaemia
NCT04965896
WITHDRAWN
NA
Effects of Stair Stepping on Late Day Postprandial Glycemia
NCT05617157
COMPLETED
NA
Breakfast Consumption and Its Effects on Glycemic, Insulinemic and Non-Esterified Fatty Acids Responses
NCT03257059
COMPLETED
NA
Evaluate Effects of Sprinkled Format REDUCOSE in a Carbohydrate-rich, Mixed Meal on Post-prandial Glycemia
NCT04877366
COMPLETED
NA
Acute Mycoprotein Effect on Glycaemic Control in South Asians
NCT03949582
UNKNOWN
NA
Metabolic Effects of Pulse Consumption on Biomarkers in Adults With Type 2 Diabetes or Met Syn
NCT05145998
COMPLETED
NA
Palm And Rice Bran Oil Study
NCT02969057
COMPLETED
NA
Glycemic Response of Bean-and-rice Meals in Type 2 Diabetes Mellitus
NCT01241253
COMPLETED
PHASE2
Cut Down on Carbohydrate Usage in the Diet of Type 2 Diabetes
NCT02764021
COMPLETED
NA